Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial transcription termination factor 2 (MTERF2) is a nuclear-encoded mitochondrial protein that binds to mitochondrial DNA and plays a regulatory role in the transcription of mitochondrial mRNA and rRNA species. It possesses DNA-binding activity and is primarily located in the mitochondrion. MTERF2 is relatively abundant within mitochondria and is thought to regulate the termination of mitochondrial transcription, influencing mitochondrial genome expression and maintenance. Mutations or alterations in MTERF2 have been associated with specific congenital anomalies and modulate susceptibility to aminoglycoside-induced deafness, but it is not a conventional therapeutic target or drug receptor[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial transcription termination factor 2 (MTERF2).